Bladder cancer, version 5.2017: Clinical Practice Guidelines in Oncology Journal Article
| Authors: | Spiess, P. E.; Agarwal, N.; Bangs, R.; Boorjian, S. A.; Buyyounouski, M. K.; Clark, P. E.; Downs, T. M.; Efstathiou, J. A.; Flaig, T. W.; Friedlander, T.; Greenberg, R. E.; Guru, K. A.; Hahn, N.; Herr, H. W.; Hoimes, C.; Inman, B. A.; Jimbo, M.; Kader, A. K.; Lele, S. M.; Meeks, J. J.; Michalski, J.; Montgomery, J. S.; Pagliaro, L. C.; Pal, S. K.; Patterson, A.; Plimack, E. R.; Pohar, K. S.; Porter, M. P.; Preston, M. A.; Sexton, W. J.; Siefker-Radtke, A. O.; Sonpavde, G.; Tward, J.; Wile, G.; Dwyer, M. A.; Gurski, L. A. |
| Article Title: | Bladder cancer, version 5.2017: Clinical Practice Guidelines in Oncology |
| Abstract: | This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up. © JNCCN - Journal of the National Comprehensive Cancer Network. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 15 |
| Issue: | 10 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2017-10-01 |
| Start Page: | 1240 |
| End Page: | 1267 |
| Language: | English |
| DOI: | 10.6004/jnccn.2017.0156 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 November 2017 -- Source: Scopus |
